Street darling Pharmacyclics upgraded at Goldman

|By:, SA News Editor

Goldman is out with some new estimates for Pharmacyclics' (PCYC) Ibrutinib.

Analyst Navdeep Singh sees a $5B opportunity in CLL and a $2.5B opportunity in MCL, WM, and DLBCL.

Singh's price target is upped to $170 (from $111), representing a 38% premium to Thursday's close.

Optimism surrounding Ibrutinib has reached a fever pitch, and some estimates peg the drug's potential as high as $9B.

PCYC +6.3% premarket.